請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77353
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 王錦堂(Jin-Town Wang) | |
dc.contributor.author | Li-Yu Hsu | en |
dc.contributor.author | 徐莉妤 | zh_TW |
dc.date.accessioned | 2021-07-10T21:57:48Z | - |
dc.date.available | 2021-07-10T21:57:48Z | - |
dc.date.copyright | 2019-08-28 | |
dc.date.issued | 2019 | |
dc.date.submitted | 2019-07-24 | |
dc.identifier.citation | 1. Global tuberculosis report 2017. World Health Organization, 2017.
2. Cambau, E. and M. Drancourt, Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. Clinical Microbiology and Infection, 2014. 20(3): p. 196-201. 3. Delogu, G., M. Sali, and G. Fadda, The biology of mycobacterium tuberculosis infection. Mediterranean Journal of Hematology and Infectious Diseases, 2013. 5(1): p. e2013070-e2013070. 4. Ohene, S.A., et al., Extra-pulmonary tuberculosis: A retrospective study of patients in Accra, Ghana. PLoS One, 2019. 14(1): p. e0209650. 5. Pai, M., et al., Tuberculosis. Nature Reviews Disease Primers, 2016. 2: p. 16076. 6. Singer-Leshinsky, S., Pulmonary tuberculosis: Improving diagnosis and management. Journal of the American Academy of PAs, 2016. 29(2): p. 20-25. 7. Ryu, Y.J., Diagnosis of pulmonary tuberculosis: recent advances and diagnostic algorithms. Tuberculosis and Respiratory Diseases, 2015. 78(2): p. 64-71. 8. Lee, J.Y., Diagnosis and treatment of extrapulmonary tuberculosis. Tuberculosis and Respiratory Diseases, 2015. 78(2): p. 47-55. 9. Sotgiu, G., et al., Tuberculosis treatment and drug regimens. Cold Spring Harbor Perspectives in Medicine, 2015. 5(5): p. a017822-a017822. 10. Kurz, S.G., J.J. Furin, and C.M. Bark, Drug-Resistant Tuberculosis: Challenges and Progress. Infectious Disease Clinics of North America, 2016. 30(2): p. 509-522. 11. Rendon, A., et al., Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives. Journal of Thoracic Disease, 2016. 8(10): p. 2666-2671. 12. Islam, M.M., et al., Drug resistance mechanisms and novel drug targets for tuberculosis therapy. Journal of Genetics and Genomics, 2017. 44(1): p. 21-37. 13. Nguyen, T.N.A., et al., Molecular Diagnosis of Drug-Resistant Tuberculosis; A Literature Review. Frontiers in Microbiology, 2019. 10: p. 794-794. 14. Falzon, D., et al., Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013. 42(1): p. 156-168. 15. Udwadia, Z. and D. Vendoti, Totally drug-resistant tuberculosis (TDR-TB) in India: every dark cloud has a silver lining. Journal of Epidemiology and Community Health, 2013. 67(6): p. 471-2. 16. Fox, H.H., The chemical approach to the control of tuberculosis. Science, 1952. 116(3006): p. 129-34. 17. Chakraborty, S. and K.Y. Rhee, Tuberculosis Drug Development: History and Evolution of the Mechanism-Based Paradigm. Cold Spring Harbor Perspectives in Medicine, 2015. 5(8): p. a021147. 18. Vilchèze, C. and W.R. Jacobs JR., Resistance to Isoniazid and Ethionamide in Mycobacterium tuberculosis: Genes, Mutations, and Causalities. Microbiology Spectrum, 2014. 2(4). 19. Somoskovi, A., L.M. Parsons, and M. Salfinger, The molecular basis of resistance to isoniazid, rifampin, and pyrazinamide in Mycobacterium tuberculosis. Respiratory Research, 2001. 2(3): p. 164-168. 20. Zhang, Y., et al., The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature, 1992. 358(6387): p. 591-3. 21. Lempens, P., et al., Isoniazid resistance levels of Mycobacterium tuberculosis can largely be predicted by high-confidence resistance-conferring mutations. Scientific reports, 2018. 8(1): p. 3246. 22. Steinhauer, K., et al., Rapid evaluation of the mycobactericidal efficacy of disinfectants in the quantitative carrier test EN 14563 by using fluorescent Mycobacterium terrae. Applied and Environmental Microbiology, 2010. 76(2): p. 546-554. 23. Parish, T. and N.G. Stoker, Use of a flexible cassette method to generate a double unmarked Mycobacterium tuberculosis tlyA plcABC mutant by gene replacement. Microbiology, 2000. 146 ( Pt 8): p. 1969-75. 24. Larsen, M.H., et al., Genetic Manipulation of Mycobacterium tuberculosis. Current Protocols in Microbiology, 2007. Chapter 10: p. Unit 10A.2. 25. Coban, A.Y., Blood agar validation for susceptibility testing of isoniazid, rifampicin, ethambutol, and streptomycin to Mycobacterium tuberculosis isolates. PLoS One, 2013. 8(2): p. e55370. 26. Johnsson, K., W.A. Froland, and P.G. Schultz, Overexpression, purification, and characterization of the catalase-peroxidase KatG from Mycobacterium tuberculosis. Journal of Biological Chemistry, 1997. 272(5): p. 2834-40. 27. Ramaswamy, S.V., et al., Single nucleotide polymorphisms in genes associated with isoniazid resistance in Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2003. 47(4): p. 1241-50. 28. Peñuelas-Urquides, K., et al., Measuring of Mycobacterium tuberculosis growth. A correlation of the optical measurements with colony forming units. Brazilian Journal of Microbiology 2013. 44(1): p. 287-289. 29. Taiwan tuberculosis control report 2017. Taiwan Centers for Disease Control, 2018. 30. Lönnroth, K. and M. Raviglione, The WHO's new End TB Strategy in the post-2015 era of the Sustainable Development Goals. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2016. 110(3): p. 148-150. 31. Yao, C., et al., Detection of rpoB, katG and inhA gene mutations in Mycobacterium tuberculosis clinical isolates from Chongqing as determined by microarray. Clinical Microbiology and Infection, 2010. 16(11): p. 1639-43. 32. Zenteno-Cuevas, R., B. Cuevas-Cordoba, and A. Parissi-Crivelli, rpoB, katG and inhA mutations in multi-drug resistant strains of Mycobacterium tuberculosis clinical isolates from southeast Mexico. Enfermedades Infecciosas y Microbiología Clínica, 2019. 37(5): p. 307-313. 33. Daum, L.T., et al., Next-Generation Sequencing for Characterizing Drug Resistance-Conferring Mycobacterium tuberculosis Genes from Clinical Isolates in the Ukraine. Journal of Clinical Microbiology, 2018. 56(6): p. e00009-18. 34. Cardoso, R.F., et al., Screening and characterization of mutations in isoniazid-resistant Mycobacterium tuberculosis isolates obtained in Brazil. Antimicrobial Agents and Chemotherapy, 2004. 48(9): p. 3373-81. 35. Brossier, F., et al., Performance of the genotype MTBDR line probe assay for detection of resistance to rifampin and isoniazid in strains of Mycobacterium tuberculosis with low- and high-level resistance. Journal of Clinical Microbiology, 2006. 44(10): p. 3659-64. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/77353 | - |
dc.description.abstract | 結核病由結核分枝桿菌(Mycobacterium tuberculosis)所引發,不僅名列全球十大死因之一,也是國內法定傳染病中每年確診數及死亡數最多的傳染病。結核病的療程需至少六個月的規律服藥,而抗藥性的產生更是其治療難度增加的主要原因。
本研究以衛生福利部疾病管制署所提供自台灣臨床分離的抗藥性菌株作為研究主題,藉由定序得知其中四株異菸鹼醯胼(Isoniazid)抗藥性菌株的KatG 蛋白分別帶有R146P、W341R、P375L 及L398P 的氨基酸序列突變,而在過去研究中上述突變皆未被記載與抗藥性有關。由藥物敏感性測試結果可得知,周教授實驗室所提供在KatG 蛋白分別帶有R146P、W341R及L398P突變的抗藥性菌株其異菸鹼醯胼最低抑制濃度都不低於128 μg/mL。 本研究藉由pMN437 載體在抗藥性菌株中表現結核分枝桿菌H37Rv 參考菌株katG 基因去探討上述基因突變與抗藥性產生的關聯。在帶有L398P氨基酸序列突變的抗藥性菌株中表現結核分枝桿菌H37Rv 參考菌株katG 基因會產生至少八倍的藥物感受性的回復;而於KatG W341R 突變株中表現結核分枝桿菌H37Rv 參考菌株katG 基因亦能看到藥物感受性的部分的回復。 為了檢測抗藥性是否因上述位點突變而有所影響。將H37Rv的katG 基因置換成katG L398P 的同源染色體置換菌株已建構完成,並將進行藥物敏感性測試確認KatG 突變是否與抗藥性的機制有關。 | zh_TW |
dc.description.abstract | Tuberculosis (TB) is a disease caused by Mycobacterium tuberculosis which is not only one of the ten major causes of death worldwide, but also recorded as the highest incidence and mortality rate among all communicable diseases in Taiwan. Since the disease takes at least 6 months to treat, the emergence of drug-resistant TB increases the difficulty of therapies.
In this study, we focus on clinically isolated drug-resistant M. tuberculosis in Taiwan, provided by the Taiwan Centers for Disease Control. The sequence of the strains was analyzed and amino acid substitutions of KatG at R146P, W341R, P375L and L398P were found in four isoniazid-resistant strains, which have not yet been reported to be related to drug-resistance. The drug susceptibility test showed that above-mentioned mutations had minimum inhibitory concentration (MIC), no less than 128 μg/mL. In this study, plasmid pMN437-katG was used to express H37Rv KatG in drug-resistant strains to investigate the correlation between the drug-resistant M. tb strains and the katG gene mutations mentioned above. The results revealed that overexpression of KatG in KatG L398P mutant strain restored drug sensitivity by more than 8 times, and KatG overexpression in KatG W341R mutant strain has partially restored the sensitivity of INH. To reconfirm the association between isoniazid-resistant phenotype and katG gene point mutations, the unmark replacement mutant substituting katG of H37Rv with katG L398P mutant was successfully constructed for further drug susceptibility test in order to study the novel katG mutation in drug resistance mechanism. | en |
dc.description.provenance | Made available in DSpace on 2021-07-10T21:57:48Z (GMT). No. of bitstreams: 1 ntu-108-R05445125-1.pdf: 1613710 bytes, checksum: ad93eed64fac2a7fa058954ed97ee53d (MD5) Previous issue date: 2019 | en |
dc.description.tableofcontents | 口試委員會審定書 I
中文摘要 II Abstract III Table of Contents IV List of tables VI List of figures VII Chapter 1 Introduction 1 1-1 Tuberculosis 1 1-2 Drug-resistant tuberculosis 2 1-3 Isoniazid (INH) 3 1-4 Objective 4 Chapter 2 Materials and Methods 5 2-1 Strains and plasmids 5 2-2 Media and reagents 5 2-3 KatG expression system 5 2-3.1 Constructs of protein expression vectors 5 2-3.2 Preparation of competent cell 6 2-3.3 katG gene expression 6 2-4 Mutant strain construction 7 2-4.1 Site-directed mutagenesis plasmid construction 7 2-4.2 Unmarked replacement plasmid construction 8 2-4.3 Chromosomal homologues recombination 8 2-5 Drug susceptibility test 9 Chapter 3 Results 11 3-1 Mutation site of katG 11 3-1.1 Drug susceptibility test for mutants from Taiwan CDC 12 3-2 KatG protein overexpression system 12 3-2.1 Protein overexpression vector construction 12 3-2.2 Drug susceptibility test for KatG protein overexpression 13 3-3 Chromosomal homologous recombination 13 3-3.1 Site-directed mutagenesis vectors construction 14 3-3.2 Unmark replacement vectors construction 15 3-3.3 Unmark replacement vector integration 16 3-3.4 Unmark replacement mutant 17 Chapter 4 Discussion and future work 18 Reference 21 | |
dc.language.iso | en | |
dc.title | katG基因突變在結核分枝桿菌之異菸鹼醯胼抗藥性中的角色 | zh_TW |
dc.title | Roles of katG gene mutations in the isoniazid drug-resistant of Mycobacterium tuberculosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 107-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 董馨蓮(Shin-Lian Doong),賴信志(Hsin-Chih Lai) | |
dc.subject.keyword | 結核分枝桿菌,抗藥性,異菸鹼醯胼,katG, | zh_TW |
dc.subject.keyword | Mycobacterium tuberculosis,drug-resistant strains,Isoniazid,katG, | en |
dc.relation.page | 40 | |
dc.identifier.doi | 10.6342/NTU201901541 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2019-07-25 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-108-R05445125-1.pdf 目前未授權公開取用 | 1.58 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。